Document vyKjp5vXLDzLMQ7oXgBxvjnq

Fyr-020/. /378 AR 22 _ 106 25 of {Na ZZ; UNITED STATESWEANSVHIIRNOGNTMONE,NTDA.CL. P2R0O4T6E0CTION AGENCY fru 2 . "4R-22-,/557 February 14, 2001 eTae rrR ase ces DuPont Haskell Laboratory Attn: Gerald L. Kennedy Director, Applied Toxicology Elkton Road, P.O. Box 50 Newark, DE 19714-0050 Com? Boe, io No car DeSarR MrC . KeEnnRedYy:dikes FR Y1-A 00-2S 013A 78 Regarding your January 25, 2001, FYI submission on ammonium perfluorooctanoate, please explain your rationale for reporting the results in this submission, as well asinyour earlier submission of June 23, 2000, as voluntary FYI submissionsratherthan under TSCA Section 8(e). In particular,theresults ofthe human blood serum tests for ammonium perfluorooctane, in combination with possible human health hazard concerns, indicate that these results should have been considered for reporting under the Section 8(e) requirementsofTSCA. Enclosed is the Confidentiality first page Claims". ofyour submission and Please cite the assigned a copy of "Support Information for FYI numberand address your response to: Document Control Office (7407) Room G99EastTower ATTN: FYI OfficeofPollution Prevention and Toxics U.S. Environmental Protection Agency < 401 M Street, S.W. = `Washington, D.C. 20460-0001 & LEAH FT S Richard H. Hefter, Chief High Production Volume Chemicals Branch Baclossise RcrdntRecrtt T 85010000n 005 ttnivtesAdionsUvALopenrsnonine 54Pe $ 00003s